RESEARCH PAPER

Stem Cell–Driven Regeneration and Oncogenic Resistance: Bioanalytical Insights into Hematologic Malignancies

[1.] Dr. S. I. Saheed Askar, [2.] Dr. Maya B. Nair, [3.]Dr. B. Subitha, [4.]Dr. Narendra Kumar Sharma, [5.]Dr. Rajendra Pujari

[1*]Assistant Professor, Microbiology, Government Medical College, Ramanathapuram. Email ID: saheedaskar@gmail.com, Orcid ID: 0009-0000-8488-4533
[2]Associate Professor, PG Department of Zoology and Research Centre, Zoology, S D College, Alappuzha,688003, Email ID: drmayabnair11@gmail.com
[3]Professor, Microbiology, Government Medical College, Ramanathapuram, Email ID: saheedaskar@gmail.com
[4]Associate Professor, Department of Chemistry, Faculty of Basic and Applied Sciences, Madhav University, Aburoad, Pindwara, Sirohi , Rajasthan 307026, Email ID: narendrasharmagwalior86@gmail.com
[5]Associate Professor, Bharati Vidyapeeth (Deemed to be University), Institute of Management and Rural Development Administration, Email ID: rajendraspujari@gmail.com

Abstract
Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, are characterized by high relapse rates and therapeutic resistance, largely driven by stem cell–mediated mechanisms. Hematopoietic stem cells and leukemic stem cells play a dual role in maintaining normal hematopoiesis and promoting tumor initiation, progression, and resistance to treatment. This review provides a comprehensive analysis of the biological and molecular mechanisms underlying stem cell–driven oncogenic resistance, including genetic and epigenetic alterations, microenvironmental interactions, drug efflux, and cellular dormancy. Advances in bioanalytical technologies, such as multi-omics profiling and single-cell analysis, have significantly enhanced the understanding of tumor heterogeneity and resistance pathways. Furthermore, emerging drug delivery strategies, including nanocarrier-based systems and targeted therapeutics, offer promising approaches to overcome biological barriers and selectively eliminate resistant stem cell populations. Despite these advances, challenges remain in clinical translation, particularly in achieving effective targeting within the bone marrow niche and addressing inter-patient variability. Future perspectives emphasize the integration of artificial intelligence, precision medicine, and next-generation delivery platforms to improve therapeutic outcomes. Overall, targeting stem cell–driven resistance represents a critical strategy for advancing toward durable remission and potential cure in hematologic malignancies.

Keywords: Hematologic malignancies, Leukemic stem cells, Oncogenic resistance, Drug delivery systems, Bioanalytical techniques

How to cite this article: Askar SIS, Nair MB, Subitha B, Sharma NK, Pujari R. Stem Cell–Driven Regeneration and Oncogenic Resistance: Bioanalytical Insights into Hematologic Malignancies. Int J Drug Deliv Technol. 2026;16(30s):999-1004. DOI: 10.25258/ijddt.16.30s.103

1. Introduction

The hematologic malignancies including leukemia, lymphoma and multiple myeloma are a heterogeneous group of cancers that originated in the hematopoietic and the lymphoid tissues. These are disorders marked by abnormal proliferation, dysdifferentiation as well as deposition of malignant cells in the bone marrow, blood and lymphatic system [1]. Although significant progress has been made in the area of diagnostics and therapeutics, such as targeted therapy and immunomodulatory treatment, these malignancies still have a significant health burden in the world because of their complicated pathophysiology and heterogeneous clinical presentation [2].

Among the most discouraging issues in the clinical management of hematologic malignancies, is that hematologic malignancies are extremely susceptible to relapse and the resistance of therapy. Despite the development of some innovative therapeutic approaches such as chimeric antigen receptor T-cell (CAR-T) therapy, currently a good portion of patients experience a first or second occurrence of the disease, which underscores the inefficacy of the current treatment modalities [3]. Mechanistically, genetic mutation, epigenetic alterations, tumor microenvironment and the immune evasion process are among the causes of resistance and disease persistence and progression.

Disease propagation, along with therapeutic resistance, is the key feature of stem cells, namely, hematopoietic stem cells (HSCs) and leukemic stem cells (LSCs). These cells are dualistic because normal stem cells play an essential role in the tissue regenerative and hematopoietic homeostasis modes, but their cancerous counterparts are the major actors in the process of tumor initiation, persistence, and recurrence. Furthermore, mesenchymal stem cells (MSCs) in the bone marrow niche also make this dynamic more complicated as they have both pro-tumorigenic and therapeutic effects and

*Author for Correspondence: saheedaskar@gmail.com

thus determine the disease progression and outcomes of the treatment [4]. Such duality discloses the complexity of the balance of regeneration and oncogenesis of the hematologic microenvironment.

The drug discovery and development processes are being changed with the advanced analytical systems such as the high-resolution mass spectrometry, multi-omics profiling and sensitive biomarker detecting systems [5,6]. The tools allow adequate characterization of the populations of the stem cells, determine resistance, and determine the pharmacodynamics and pharmacokinetics of novel therapeutics.

Moreover, bioanalysis with the complex of developing drug delivery has good prospects of preventing therapeutic resistance. Some of these delivery systems such as nanocarriers and biologics are directed towards eliminating intractable populations of low-toxicity stem cells to the system. These cross-functional interventions are applicable to enhancing the efficacy of the treatment and delivery of sustainable clinical reactions among the patients having hematologic malignancies.

Objectives

1. To elucidate the role of stem cells in driving oncogenic resistance in hematologic malignancies
2. To assess bioanalytical approaches for identifying resistance mechanisms and biomarkers
3. To evaluate advanced drug delivery strategies targeting resistant stem cell populations

4. Stem Cell Biology in Hematologic Systems

The multipotent Hematopoietic stem cells (HSCs) are cells that generate blood cells in a highly regulated self-renewal and differentiation program in specific bone marrow niches throughout the lifespan [7]. They are regulated by their intrinsic transcriptional programs and extrinsic stimuli including cytokines and metabolic factors that all work together to keep the hematopoietic homeostasis in the bloodstream [8]. Regenerative capacity is also affected by metabolic factors such as nutrient supply, and cellular metabolism is associated with stem cell activity [9]. Nevertheless, epigenetic changes related to aging may degrade the action of HSC and precondition the malignant change [10].

The drivers of tumor formation, progression and relapse are the LSCs produced by differentiation of HSCs or progenitors because of its self-renewability and resistance to therapy [11]. The cells are hierarchically structured, with distinct molecular signatures, and hence heterogeneous to disease [12]. Also, plasticity of stem cells and clonal evolution allow them to adapt to therapeutic pressure, allowing the clonal lineage to switch and increase in number. These dynamic changes that in most cases are affected by epigenetic regulation and mutation accumulation underline the complexity of the hematologic malignancies and the need to have specific therapeutic strategies [13]. Table 1 showing the comparison between hematopoietic stem cells and leukemic stem cells.

Table 1. Comparative Features of Hematopoietic Stem Cells and Leukemic Stem Cells

Feature	HSCs	LSCs	References
Origin	Normal hematopoietic stem cells	Transformed HSCs or progenitor cells	[7]
Function	Maintain lifelong hematopoiesis	Initiate, sustain, and propagate leukemia	[7,12]
Self-renewal	Tightly regulated	Aberrant and persistent	[8, 12]
Differentiation	Normal multilineage differentiation	Blocked or dysregulated differentiation	[7,11]
Phenotype	Commonly $CD34^{+}CD38^{-}$ with normal stemness markers	Often $CD34^{+}CD38^{-}$ with leukemia-associated markers such as CD123	[12]
Genomic state	Relatively stable	Carries oncogenic mutations	[12,14]
Therapy response	Supports recovery after treatment	Frequently resistant to therapy	[15]
Clinical relevance	Essential for regeneration and transplantation	Major driver of relapse and poor prognosis	[8]

5. Mechanisms of Oncogenic Resistance

The complexity of the interactions between genetic, epigenetic, cellular, and microenvironmental factors that promote the persistence and relapse of tumors is the cause of oncogenic resistance in hematologic malignancies. The essence of the disease progression and treatment resistance is genetic modification, including FLT3, NPM1, and BCR-ABL driver mutations, which increase the incontrolled proliferation and survival signaling pathways [14]. Simultaneously, dynamic regulation of gene expression through epigenetic changes like histone modifications and DNA methylation changes does not change the sequence of the DNA and instead promotes adaptive resistance and phenotypic plasticity [16]. Notably, the non-genetic mechanisms also play a role in resistance because they allow reversible cellular states that facilitate survival to therapeutic stress [15].

Bone marrow niche and the tumor microenvironment in general offer a safe haven to malignant stem cells. The contacts with the stromal cells, cytokines and the extracellular matrix elements facilitate survival and provide protection to the cancer cells against the cytotoxic agents [17]. The resulting hypoxia of this niche leads to additional metabolic reprogramming and resistance to changes in metabolic energy use and increased drug sensitivity [18].

Also, there is an active efflux of drug especially ATP-binding cassade (ABC) transporters that decrease drug build up in cells, thus, lowering therapeutic effects [19].

Another mechanism of high importance is cellular quiescence and dormancy, which enables the stem-like cells to avoid therapies that are designed to eliminate growing populations [20]. Lastly, malignant cells can avoid immune surveillance through immune evasion measures, such as immune cell interactions and immune signaling pathways modulation, further promoting the persistence of diseases [21].

7. Drug Delivery Strategies Targeting Stem Cell Niches

The use of stem cell niches in the treatment of hematologic malignancies requires the use of advanced drug delivery systems that can bypass the biologic obstacles as well as selectively kill the resistant groups of cells. Certain nanocarrier-based systems including liposomes, polymeric nanoparticles, and dendrimers have been employed in the improvement of the stability, bioavailability and specific delivery of drugs to the cancer cells. The release and accumulation in the bone marrow microenvironment are controlled in these systems, and therefore enhance the therapeutic efficacy, and decrease systemic toxicity. Interaction with bioanalytical systems also promotes the determination of the cellular uptake and pharmacokinetics correctly [22].

The specific surface markers (e.g., CD34 and CD123) are the basis of selective methods of delivering targeted drugs targeting leukemic stem cells (LSCs) to enhance its specificity and reduce off-target effects [23]. The identification and the validation of these targets can be achieved with the assistance of the sophisticated analytical techniques, including flow cytometry and single-cell profiling, which assists in performing a more precise therapeutic intervention [24]. Also, the technologies of spatial omics can help to understand the microenvironment of tumors and can be used in developing niche delivery approaches [25].

The dynamic release of drugs can be provided by stimuli-sensitive systems, like pH-sensitive and redox-sensitive carriers, in response to the specifics of the tumor microenvironment. Therapeutics, such as siRNA, miRNA, and CRISPR systems, are based on genes and RNA, which further increases the treatment options by providing the ability to regulate the resistance-related genes [26]. Besides, it is still essential to overcome biological obstacles, including the low penetration of bone marrow and drug efflux, and the liquid biopsy technology can assist in the real-time evaluation of the therapeutic effect and disease development [27].

8. Therapeutic Strategies to Overcome Resistance

The treatment of hematologic malignancies in patients presenting with therapeutic resistance necessitates the application of multifaceted approaches that will address the malignant stem cells and their supportive microenvironment. Synchronous interference with multiple oncogenic pathways by targeting them with combination therapies, which combine targeted agents with standard chemotherapy, has shown increased effectiveness. There are also epigenetic drugs that regulate DNA methylation, histone modification, which are also being used to reverse aberrant gene expression pattern linked to resistance [28].

The field of immunotherapy has become a revolutionary one, especially due to the introduction of chimeric antigen receptor T-cell (CAR-T) therapy and monoclonal antibodies [29]. Such modalities allow the tumor cells to be targeted more specifically with the exploitation of the body immune system, but the resistance and relapse continues to be a challenge. The delivery systems, such as nanocarriers-based platforms, designed DNA nanoarchitectures, also promote the selectivity and efficacy of immunotherapeutic agents [30].

What is equally important is to target the stem cell niche since the bone marrow microenvironment offers protective signals that support leukemic stem cells. The CXCR4 inhibitors are some of the agents that block these interactions, exposing malignant cells to therapy. At the same time, stimuli-responsive drug delivery systems can allow to precisely release drugs in the tumor microenvironment in a localized and controlled manner [31].

Tailored treatment can be achieved by the integration of personalized and precision medicine approaches which are being driven by the discovery of biomarkers and RNA-based therapeutics. New modalities like siRNA and gene-based therapies may provide an opportunity to directly target resistance-associated pathways and thus, enhance clinical outcomes [32].

9. Clinical Translation and Current Trials

The clinical development of leukemic stem cells (LSCs) therapeutic approaches has gained a lot of momentum due to the progress in the elucidation of resistance mechanisms and stem cell biology. Continued clinical trials are progressively aimed at eliminating LSCs using specific therapeutic methods, immunotherapeutic methods, and combination therapies that aim at overcoming inherent and acquired resistance [33]. Such strategies as small-molecule inhibitors, monoclonal antibodies, and CAR-T cell therapies are being actively discussed with reference to their selection of resistant populations of cells and increased long-term remission rates [40]. Specifically, CAR-T cell therapy has already shown good clinical results in hematologic malignancies, but the issues of relapse and antigen evasion remain [41].

A number of approved therapies have already started doing this, targeting distinct molecular pathways and microenvironmental interactions, to deal with resistance. They are agents that impair stem cell niche communication and agents that are aimed at sensitizing the malignant cells to the traditional therapies. The increased appreciation of the stem cell niche as a stringent disease progression regulator has also guided the formulation of niche-based interventions [42].

With such improvements, there are still many gaps in translation. The constraint with the effective targeting of heterogeneous populations of LSCs, variance of patient response, and inherent difficulties in delivering drugs to safeguarded micro environment remain barriers to clinical success. Moreover, the application of precision medicine strategies that are facilitated by modern diagnostic and analytical methods is not fully implemented, which is why more powerful biomarker-oriented strategies should be used [43]. These challenges must be faced to bring up new therapies into sustained clinical results (Table 2).

Table 2. Current Therapeutic Strategies and Clinical Status

Strategy	Clinical status	References
Combination therapy	Standard approach; improves response and delays resistance	[33]
Epigenetic therapy	Used in resistant/relapsed settings, mainly in combinations	[33]
CAR-T cell therapy	Approved for selected hematologic malignancies; relapse remains a limitation	[41]
Monoclonal antibodies	Clinically established and widely integrated into treatment regimens	[40]
Stem cell niche disruption	Emerging strategy under clinical evaluation	[42]
Precision medicine	Expanding through biomarker-guided therapy selection	[43]

10. Challenges and Limitations

Although there has been a major advancement, there are still a number of issues that have been identified to slow down effective translation of stem cell-targeted therapies in hematologic malignancies. The main limitation of current model systems is that they simply may not be able to recap the complexity of human illness, particularly the dynamic processes of malignant stem cells in their microenvironment. This reduces predictability of the preclinical activity and complicates the clinical translation [44]. Delivery of drugs is also an important obstacle since efficient and selective penetration of drug into resistant stem cell niches like the bone marrow is in itself challenging. Even though new delivery methods like extracellular vesicles hold futuristic potential in terms of delivery, the problem of scalability, target delivery specificity, and manufacturing consistency is yet to be sorted out [45]. Simultaneously, bioanalytical drawbacks are still present when it comes to the identification and description of uncommon resistant cell groups. Lack of analytical sensitivity may result in blurring of treatment response biomarkers and impede proper monitoring of treatment response [46]. Although more complex multi-omics and analytics systems built on artificial intelligence are enhancing data integration and comprehensibility, they are still technically and computationally costly to use in a regular clinical environment [47]. In addition, the high inter-patient differences in genetic predisposition, disease progression and response to therapy make the standardization challenging and less generalizable treatment strategies. This and other restrictions bring to mind the necessity to have more physiologically based models, powerful analytical platforms and tailor-made therapeutic models.

11. Future Perspectives

Nevertheless, the intersection of artificial intelligence (AI) and multi-omics technologies is becoming increasingly important to the management of hematologic malignancies, as it is possible to combine genomic, transcriptomic, proteomic, and metabolomic data extensively and uncover more complex resistance processes and novel drug targets, which are recognized with high specificity. Such data-driven solutions are likely to assist in reaching a tremendous increase in predictive diagnostics and the growth of popularity of personal treatment plans. Simultaneously, there are biomimetic nanoparticles, extracellular vesicles, and programmable delivery systems which are the next generation drug delivery platforms to improve targeting of leukemic stem cells with minimal systemic toxicity to overcome one of the biggest drawbacks of current treatment. Nevertheless, the problem of the tradeoff between the regenerative potential of the stem cell-based treatment and the threat of oncogenic conversion is the most important one, and it requires a more profound insight into the plasticity of the stem cells and their contribution to the development of malignant tissue. The integration of advanced bioanalytics, precision medicine, and targeted delivery systems have a promising future of changing the therapeutic paradigm of conventional disease management to curative options, by effectively eliminating resistant populations of stem cells and achieving long term remission.

12. Conclusion

The complexity, heterogeneity, and the presence of therapy resistant populations of stem cells that result into relapse and disease progression have made hematologic malignancies to remain a significant clinical challenge. This review provides a crucial role of hematopoietic and leukemic stem cells in the functioning of regenerative and oncogenic resistance as well as accumulation of genetic, epigenetic and microenvironmental factors leading to therapeutic failure. The bioanalytical technologies have enabled one to learn more about such mechanisms, as key biomarkers and resistant cellular subpopulations can be identified. Meanwhile, there are promising opportunities of new drug delivery methods, including nanocarriers and targeted delivery, to selectively kill leukemic stem cells and to avoid biological adverse effects, including, but not limited to, bone marrow niche and drug efflux. However, it continues to be faced with some severe translational problems including limitation of preclinical model, inter-patient variability, and the issue of accurate targeting of complex microenvironment. The future of multi-omics, artificial intelligence, and precision medicine approaches is a combination of all of them, which will be the key to developing more efficient and personalized treatment. Lastly, eradication of stem cell induced resistance is a key step towards achievement of long-term remission and gradual curative therapy of hematologic malignancies.

References

1. Rosmarin, A. (2019). Leukemia, lymphoma, and myeloma. *Cancer: Prevention, early detection, treatment and recovery*, 299-316.
2. Allegra, A., Tonacci, A., Musolino, C., Pioggia, G., & Gangemi, S. (2021). Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia. *Frontiers in immunology*, *12*, 738915.
3. Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024). Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy. *Expert review of clinical immunology*, *20*(7), 745-763.
4. Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023). The dual role of mesenchymal stem cells in cancer pathophysiology: pro-tumorigenic effects versus therapeutic potential. *International Journal of Molecular Sciences*, *24*(17), 13511.
5. Shi, J., Chen, X., Diao, J., Jiang, L., Li, L., Li, S., ... & Tse, F. L. (2021). Bioanalysis in the age of new drug modalities. *The AAPS Journal*, *23*(3), 64.
6. Thakur, A., Tan, Z., Kameyama, T., El-Khateeb, E., Nagpal, S., Malone, S., ... & Nwabufo, C. K. (2021). Bioanalytical strategies in drug discovery and development. *Drug Metabolism Reviews*, *53*(3), 434-458.
7. Dzierzak, E., & Bigas, A. (2018). Blood development: hematopoietic stem cell dependence and independence. *Cell stem cell*, *22*(5), 639-651.
8. Mann, Z., Sengar, M., Verma, Y. K., Rajalingam, R., & Raghav, P. K. (2022). Hematopoietic stem cell factors: their functional role in self-renewal and clinical aspects. *Frontiers in Cell and Developmental Biology*, *10*, 664261.
9. Qi, L., Martin-Sandoval, M. S., Merchant, S., Gu, W., Eckhardt, M., Mathews, T. P., ... & Morrison, S. J. (2021). Aspartate availability limits hematopoietic stem cell function during hematopoietic regeneration. *Cell stem cell*, *28*(11), 1982-1999.
10. Ermolaeva, M., Neri, F., Ori, A., & Rudolph, K. L. (2018). Cellular and epigenetic drivers of stem cell ageing. *Nature reviews Molecular cell biology*, *19*(9), 594-610.
11. Chopra, M., & Bohlander, S. K. (2019). The cell of origin and the leukemia stem cell in acute myeloid leukemia. *Genes, Chromosomes and Cancer*, *58*(12), 850-858.
12. Long, N. A., Golla, U., Sharma, A., & Claxton, D. F. (2022). Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. *Stem cell reviews and reports*, *18*(4), 1211-1226.
13. Uryu, H., Saeki, K., Haeno, H., Kapadia, C. D., Furudate, K., Nangalia, J., ... & Takahashi, K. (2025). Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation. *Nature genetics*, *57*(7), 1695-1707.
14. Wang, M., Bolli, N., & Vassiliou, G. S. (2025). The molecular basis of haematological malignancies. *Hoffbrand's Postgraduate Haematology*, 121-141.
15. Marine, J. C., Dawson, S. J., & Dawson, M. A. (2020). Non-genetic mechanisms of therapeutic resistance in cancer. *Nature Reviews Cancer*, *20*(12), 743-756.
16. Gagnidze, K., & Pfaff, D. W. (2022). Epigenetic mechanisms: DNA methylation and histone protein modification. In *Neuroscience in the 21st century: from basic to clinical* (pp. 2677-2716). Cham: Springer International Publishing.
17. Borlongan, M. C., Saha, D., & Wang, H. (2024). Tumor microenvironment: a niche for cancer stem cell immunotherapy. *Stem Cell Reviews and Reports*, *20*(1), 3-24.
18. Bao, M. H. R., & Wong, C. C. L. (2021). Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. *Cells*, *10*(7), 1715.
19. Koehn, L. M. (2022). ABC transporters: an overview. *The ADME encyclopedia: a comprehensive guide on biopharmacy and pharmacokinetics*, 1-10.
20. Eljebbawi, A., Dolata, A., Strotmann, V. I., & Stahl, Y. (2024). Stem cell quiescence and dormancy in plant meristems. *Journal of Experimental Botany*, *75*(19), 6022-6036.
21. Minkoff, J. M., & tenOever, B. (2023). Innate immune evasion strategies of SARS-CoV-2. *Nature Reviews Microbiology*, *21*(3), 178-194.
22. Hays, A., Durham, J., Gullick, B., Rudemiller, N., & Schneider, T. (2022). Bioanalytical assay strategies and considerations for measuring cellular kinetics. *International Journal of Molecular Sciences*, *24*(1), 695.
23. Telford, W. G. (2023). Flow cytometry and cell sorting. *Frontiers in Medicine*, *10*, 1287884.
24. Zhu, Z., Jiang, L., & Ding, X. (2023). Advancing breast cancer heterogeneity analysis: insights from genomics, transcriptomics and proteomics at bulk and single-cell levels. *Cancers*, *15*(16), 4164.
25. Lewis, S. M., Asselin-Labat, M. L., Nguyen, Q., Berthelet, J., Tan, X., Wimmer, V. C., ... & Naik, S. H. (2021). Spatial omics and multiplexed imaging to

explore cancer biology. *Nature methods*, *18*(9), 997-1012.

26. Soda, N., Rehm, B. H., Sonar, P., Nguyen, N. T., & Shiddiky, M. J. (2019). Advanced liquid biopsy technologies for circulating biomarker detection. *Journal of Materials Chemistry B*, *7*(43), 6670-6704.
27. Dathathri, E., Isebia, K. T., Abali, F., Lolkema, M. P., Martens, J. W., Terstappen, L. W., & Bansal, R. (2022). Liquid biopsy based circulating biomarkers in metastatic prostate cancer. *Frontiers in oncology*, *12*, 863472.
28. Cao, J., Bhatnagar, S., Wang, J., Qi, X., Prabha, S., & Panyam, J. (2021). Cancer stem cells and strategies for targeted drug delivery. *Drug delivery and translational research*, *11*(5), 1779-1805.
29. Antonelli, A., & Palma, F. (2025). Nanocarrier-based delivery systems for natural compounds across research stages. *Materials*, *18*(21), 4960.
30. Dwivedy, A., Baskaran, D., Sharma, G., Hong, W., Gandavadi, D., Krissanaprasit, A., ... & Wang, X. (2025). Engineering novel DNA nanoarchitectures for targeted drug delivery and aptamer mediated apoptosis in cancer therapeutics. *Advanced Functional Materials*, *35*(22), 2425394.
31. Wells, C. M., Harris, M., Choi, L., Murali, V. P., Guerra, F. D., & Jennings, J. A. (2019). Stimuli-responsive drug release from smart polymers. *Journal of functional biomaterials*, *10*(3), 34.
32. Zhou, L. Y., Qin, Z., Zhu, Y. H., He, Z. Y., & Xu, T. (2019). Current RNA-based therapeutics in clinical trials. *Current Gene Therapy*, *19*(3), 172-196.
33. Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024). Emerging therapeutic strategies to overcome drug resistance in cancer cells. *Cancers*, *16*(13), 2478.
34. Kobylka, J., Kuth, M. S., Müller, R. T., Geertsma, E. R., & Pos, K. M. (2020). AcrB: a mean, keen, drug efflux machine. *Annals of the New York academy of sciences*, *1459*(1), 38-68.
35. Vergalli, J., Atzori, A., Pajovic, J., Dumont, E., Malloci, G., Masi, M., ... & Pagès, J. M. (2020). The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux. *Communications Biology*, *3*(1), 198.
36. Lewis, S. M., Asselin-Labat, M. L., Nguyen, Q., Berthelet, J., Tan, X., Wimmer, V. C., ... & Naik, S. H. (2021). Spatial omics and multiplexed imaging to explore cancer biology. *Nature methods*, *18*(9), 997-1012.
37. Armbrust, M., Ghodsi, A., Xin, R., & Zaharia, M. (2021, January). Lakehouse: a new generation of open platforms that unify data warehousing and advanced analytics. In *Proceedings of CIDR* (Vol. 8, No. 1, p. 28). sn.
38. Antonelli, A., & Palma, F. (2025). Nanocarrier-based delivery systems for natural compounds across research stages. *Materials*, *18*(21), 4960.
39. Zhou, L. Y., Qin, Z., Zhu, Y. H., He, Z. Y., & Xu, T. (2019). Current RNA-based therapeutics in clinical trials. *Current Gene Therapy*, *19*(3), 172-196.
40. Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., ... & Wang, H. (2025). Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. *Molecular biomedicine*, *6*(1), 2.
41. Miliotou, A. N., & Papadopoulou, L. C. (2018). CAR T-cell therapy: a new era in cancer immunotherapy. *Current pharmaceutical biotechnology*, *19*(1), 5-18.
42. Hicks, M. R., & Pyle, A. D. (2023). The emergence of the stem cell niche. *Trends in cell biology*, *33*(2), 112-123.
43. Ho, D., Quake, S. R., McCabe, E. R., Chng, W. J., Chow, E. K., Ding, X., ... & Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. *Trends in biotechnology*, *38*(5), 497-518.
44. Li, C. (2022). Strengthening regulations, recent advances and remaining barriers in stem cell clinical translation in China: 2015–2021 in review. *Pharmacological Research*, *182*, 106304.
45. Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021). Extracellular vesicles as a next-generation drug delivery platform. *Nature nanotechnology*, *16*(7), 748-759.
46. Yetgin, A. (2025). Revolutionizing multi-omics analysis with artificial intelligence and data processing. *Quantitative Biology*, *13*(3), e70002.
47. Tong, L., Shi, W., Isgut, M., Zhong, Y., Lais, P., Gloster, L., ... & Wang, M. D. (2023). Integrating multi-omics data with EHR for precision medicine using advanced artificial intelligence. *IEEE Reviews in Biomedical Engineering*, *17*, 80-97.